ASX Announcement September 2026 Quarterly Activities Report & Appendix 4C ? First patient safely treated with RC220 & osimertinib in the HARNESS-1 trial for patients with EGFR-mutated non-small cell lung cancer ? Phase 1 CPACS trial expands to South Korea, allowing for accelerated patient...
Sept 2026 Quarterly Activities Report and Appendix 4C
Filed with ASX · · 12 pages · English
Summary by 6ix AI
Racura reported a strong cash balance at the end of the quarter, with a substantial portion of expenditures directed towards research and development activities. The company continues to progress its clinical programs and has received ethics approvals for additional trial sites, supporting its ongoing research efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Racura Oncology
- HARNESS-1 First Cohort Cleared
- Racura Presents CPACS Data at GCOS 2026
- Date of AGM & Closing Date for Director Nominations
- Appendix 3Y - Dr Daniel Tillett
- RC220 MYC-silencing data to be presented FCS 26 conference
Later from Racura Oncology
- Letter to Shareholders, Notice of AGM & Proxy Form
- Racura Presents Bisantrene MYC Data at FCS 2026
- Racura Successfully PK Bridges RC110 RC220
- Sheba Grants Ethics Approval for EMILI AML Trial
- EMILI Investor Webinar Nov 2026
